Inadequate Blinding Associated With Positive Treatment Findings, Industrial Sponsorship, and Schizophrenia Diagnosis


Despite the integral importance of blinding and blinding assessment to randomized controlled trials (RCTs), they are rarely reported on or documented in trial reports according to this study published yesterday in Psychotherapy and Psychosomatics. The study of schizophrenia and affective disorder medication research in 2,467 publications from 2000 to 2010 found that an absence of blinding and blinding assessment was associated with an increased rate of positive findings of treatment success, industrial sponsorship, and diagnosis of schizophrenia.

Abstract →

Baethge, C., Assall, O.P., Baldessarini, R.J., Systematic Review of Blinding Assessment in Randomized Controlled Trials in Schizophrenia and Affective Disorders 2000-2010. Psychotherapy and Psychosomatics. Online March 25, 2013

Previous articleCompulsory Supervision Does Not Reduce Hospital Re-Admissions
Next articleExcessive Mood & Behavior Arousal in Juveniles Treated with Antidepressants
Kermit Cole
Kermit Cole, MFT, founding editor of Mad in America, works in Santa Fe, New Mexico as a couples and family therapist. Inspired by Open Dialogue, he works as part of a team and consults with couples and families that have members identified as patients. His work in residential treatment — largely with severely traumatized and/or "psychotic" clients — led to an appreciation of the power and beauty of systemic philosophy and practice, as the alternative to the prevailing focus on individual pathology. A former film-maker, he has undergraduate and master's degrees in psychology from Harvard University, as well as an MFT degree from the Council for Relationships in Philadelphia. He is a doctoral candidate with the Taos Institute and the Free University of Brussels. You can reach him at [email protected].